Administration of BAY 41-2272 prevents bladder dysfunction in nitric-oxide deficient rats

Detalhes bibliográficos
Autor(a) principal: D'Ancona,Carlos Arturo Levi
Data de Publicação: 2010
Outros Autores: Mónica,Fabíola Zakia Taufic, Reges,Ricardo, Cohen,David, Silva,Fabio Henrique da, Nucci,Gilberto De, Antunes,Edson
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Einstein (São Paulo)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082010000400404
Resumo: ABSTRACT Objective: to evaluate the protective effects of BAY 41-2272, a soluble guanylate cyclase activator, on changes in cystometric parameters in rats deficient in nitric oxide (NO). Methods: Rats were divided into the following groups: (a) control; (b) DMSO; (c) L-NAME; (d) BAY 41-2272 alone; (e) L-NAME + BAY 41-2272. The NO synthase blocker L-NAME (20 mg/rat/day) was given in drinking water concomitantly or not with BAY 41-2272 (10 mg/kg/day, given by gavage). Results: Chronic L-NAME treatment markedly increased the mean arterial blood pressure, and co-treatment with BAY 41-2272 nearly reversed L-NAME-induced rise on mean arterial blood pressure. Non-void contractions were significantly increased in L-NAME group (0.90 ± 0.1 number/minute) compared with either DMSO or control group (0.49 ± 0.1 number/minute), which were prevented by co-treatment with BAY 41-2272 (0.56 ± 025 number/minute; p < 0.05). The threshold and peak pressure increased by 70 and 44%, respectively, after chronic L-NAME treatment, while co-treatment with BAY 41-2272 largely attenuated both effects (27 and 22% increase, respectively). The frequency of micturition cycles decreased by about of 50% in L-NAME-treated rats compared with control animals, and co-treatment with BAY 41-2272 normalized this parameter. Conclusions: Our data show that long-term oral administration of BAY 41-2272 counteracts the bladder dysfunction seen in NO-deficient rats, indicating that restoration of the NO-cGMP pathway by this compound may be of beneficial value to treat bladder symptoms.
id IIEPAE-1_901ebee6d620fd8e395f1959e9dc2464
oai_identifier_str oai:scielo:S1679-45082010000400404
network_acronym_str IIEPAE-1
network_name_str Einstein (São Paulo)
repository_id_str
spelling Administration of BAY 41-2272 prevents bladder dysfunction in nitric-oxide deficient ratsGuanylate cyclaseNitric oxideUrinary bladder, overactiveRatsABSTRACT Objective: to evaluate the protective effects of BAY 41-2272, a soluble guanylate cyclase activator, on changes in cystometric parameters in rats deficient in nitric oxide (NO). Methods: Rats were divided into the following groups: (a) control; (b) DMSO; (c) L-NAME; (d) BAY 41-2272 alone; (e) L-NAME + BAY 41-2272. The NO synthase blocker L-NAME (20 mg/rat/day) was given in drinking water concomitantly or not with BAY 41-2272 (10 mg/kg/day, given by gavage). Results: Chronic L-NAME treatment markedly increased the mean arterial blood pressure, and co-treatment with BAY 41-2272 nearly reversed L-NAME-induced rise on mean arterial blood pressure. Non-void contractions were significantly increased in L-NAME group (0.90 ± 0.1 number/minute) compared with either DMSO or control group (0.49 ± 0.1 number/minute), which were prevented by co-treatment with BAY 41-2272 (0.56 ± 025 number/minute; p < 0.05). The threshold and peak pressure increased by 70 and 44%, respectively, after chronic L-NAME treatment, while co-treatment with BAY 41-2272 largely attenuated both effects (27 and 22% increase, respectively). The frequency of micturition cycles decreased by about of 50% in L-NAME-treated rats compared with control animals, and co-treatment with BAY 41-2272 normalized this parameter. Conclusions: Our data show that long-term oral administration of BAY 41-2272 counteracts the bladder dysfunction seen in NO-deficient rats, indicating that restoration of the NO-cGMP pathway by this compound may be of beneficial value to treat bladder symptoms.Instituto Israelita de Ensino e Pesquisa Albert Einstein2010-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082010000400404einstein (São Paulo) v.8 n.4 2010reponame:Einstein (São Paulo)instname:Instituto Israelita de Ensino e Pesquisa Albert Einstein (IIEPAE)instacron:IIEPAE10.1590/s1679-45082010ao1789info:eu-repo/semantics/openAccessD'Ancona,Carlos Arturo LeviMónica,Fabíola Zakia TauficReges,RicardoCohen,DavidSilva,Fabio Henrique daNucci,Gilberto DeAntunes,Edsoneng2017-03-14T00:00:00Zoai:scielo:S1679-45082010000400404Revistahttps://journal.einstein.br/pt-br/ONGhttps://old.scielo.br/oai/scielo-oai.php||revista@einstein.br2317-63851679-4508opendoar:2017-03-14T00:00Einstein (São Paulo) - Instituto Israelita de Ensino e Pesquisa Albert Einstein (IIEPAE)false
dc.title.none.fl_str_mv Administration of BAY 41-2272 prevents bladder dysfunction in nitric-oxide deficient rats
title Administration of BAY 41-2272 prevents bladder dysfunction in nitric-oxide deficient rats
spellingShingle Administration of BAY 41-2272 prevents bladder dysfunction in nitric-oxide deficient rats
D'Ancona,Carlos Arturo Levi
Guanylate cyclase
Nitric oxide
Urinary bladder, overactive
Rats
title_short Administration of BAY 41-2272 prevents bladder dysfunction in nitric-oxide deficient rats
title_full Administration of BAY 41-2272 prevents bladder dysfunction in nitric-oxide deficient rats
title_fullStr Administration of BAY 41-2272 prevents bladder dysfunction in nitric-oxide deficient rats
title_full_unstemmed Administration of BAY 41-2272 prevents bladder dysfunction in nitric-oxide deficient rats
title_sort Administration of BAY 41-2272 prevents bladder dysfunction in nitric-oxide deficient rats
author D'Ancona,Carlos Arturo Levi
author_facet D'Ancona,Carlos Arturo Levi
Mónica,Fabíola Zakia Taufic
Reges,Ricardo
Cohen,David
Silva,Fabio Henrique da
Nucci,Gilberto De
Antunes,Edson
author_role author
author2 Mónica,Fabíola Zakia Taufic
Reges,Ricardo
Cohen,David
Silva,Fabio Henrique da
Nucci,Gilberto De
Antunes,Edson
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv D'Ancona,Carlos Arturo Levi
Mónica,Fabíola Zakia Taufic
Reges,Ricardo
Cohen,David
Silva,Fabio Henrique da
Nucci,Gilberto De
Antunes,Edson
dc.subject.por.fl_str_mv Guanylate cyclase
Nitric oxide
Urinary bladder, overactive
Rats
topic Guanylate cyclase
Nitric oxide
Urinary bladder, overactive
Rats
description ABSTRACT Objective: to evaluate the protective effects of BAY 41-2272, a soluble guanylate cyclase activator, on changes in cystometric parameters in rats deficient in nitric oxide (NO). Methods: Rats were divided into the following groups: (a) control; (b) DMSO; (c) L-NAME; (d) BAY 41-2272 alone; (e) L-NAME + BAY 41-2272. The NO synthase blocker L-NAME (20 mg/rat/day) was given in drinking water concomitantly or not with BAY 41-2272 (10 mg/kg/day, given by gavage). Results: Chronic L-NAME treatment markedly increased the mean arterial blood pressure, and co-treatment with BAY 41-2272 nearly reversed L-NAME-induced rise on mean arterial blood pressure. Non-void contractions were significantly increased in L-NAME group (0.90 ± 0.1 number/minute) compared with either DMSO or control group (0.49 ± 0.1 number/minute), which were prevented by co-treatment with BAY 41-2272 (0.56 ± 025 number/minute; p < 0.05). The threshold and peak pressure increased by 70 and 44%, respectively, after chronic L-NAME treatment, while co-treatment with BAY 41-2272 largely attenuated both effects (27 and 22% increase, respectively). The frequency of micturition cycles decreased by about of 50% in L-NAME-treated rats compared with control animals, and co-treatment with BAY 41-2272 normalized this parameter. Conclusions: Our data show that long-term oral administration of BAY 41-2272 counteracts the bladder dysfunction seen in NO-deficient rats, indicating that restoration of the NO-cGMP pathway by this compound may be of beneficial value to treat bladder symptoms.
publishDate 2010
dc.date.none.fl_str_mv 2010-12-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082010000400404
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082010000400404
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/s1679-45082010ao1789
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Instituto Israelita de Ensino e Pesquisa Albert Einstein
publisher.none.fl_str_mv Instituto Israelita de Ensino e Pesquisa Albert Einstein
dc.source.none.fl_str_mv einstein (São Paulo) v.8 n.4 2010
reponame:Einstein (São Paulo)
instname:Instituto Israelita de Ensino e Pesquisa Albert Einstein (IIEPAE)
instacron:IIEPAE
instname_str Instituto Israelita de Ensino e Pesquisa Albert Einstein (IIEPAE)
instacron_str IIEPAE
institution IIEPAE
reponame_str Einstein (São Paulo)
collection Einstein (São Paulo)
repository.name.fl_str_mv Einstein (São Paulo) - Instituto Israelita de Ensino e Pesquisa Albert Einstein (IIEPAE)
repository.mail.fl_str_mv ||revista@einstein.br
_version_ 1752129905864212480